Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PKN605 · 1 trial · 1 indication
Defined as the amount of time spent in atrial fibrillation as a proportion of the analyzable monitoring time
| Arm | Type | Description |
|---|---|---|
| PKN605 lower dose | EXPERIMENTAL | PKN605 is an oral formulation |
| PKN605 higher dose | EXPERIMENTAL | PKN605 is an oral formulation |
| Placebo | PLACEBO_COMPARATOR | Placebo is an oral formulation |
| Name | Type | Description |
|---|---|---|
| PKN605 | DRUG | PKN605 is an oral formulation |
| Placebo | OTHER | Matching placebo |
Inclusion Criteria: * Inclusions at Screening * Signed informed consent must be obtained prior to participation in the study * Male and female participants ≥ 18 years of age * History of at least 2 episodes of AF (atrial fibrillation or atrial flutter), at least one episode must be atrial fi...